-
公开(公告)号：US20240141389A1
公开(公告)日：2024-05-02
申请号：US18296235
申请日：2023-04-05
发明人： David J. Rawlings , Iram Khan
CPC分类号： C12N15/907 , C12N9/22
摘要： Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
-
公开(公告)号：US20240117008A1
公开(公告)日：2024-04-11
申请号：US18446018
申请日：2023-08-08
IPC分类号： C07K14/715 , C12N15/62
CPC分类号： C07K14/7155 , C12N15/62 , C07K2317/53 , C07K2319/02 , C07K2319/03
摘要： The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.
-
3.发明公开公开(公告)号：US20230172981A1
公开(公告)日：2023-06-08
申请号：US17758960
申请日：2021-02-02
IPC分类号： A61K35/17 , C07K14/725
CPC分类号： A61K35/17 , C07K14/7051
摘要： Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
-
公开(公告)号：US20220062461A1
公开(公告)日：2022-03-03
申请号：US17463245
申请日：2021-08-31
申请人： University of Washington , Seattle Children's Hospital (dba Seattle Children's Research Institute)
发明人： James Chen , Tanner Clark , Thomas Lendvay
摘要： Methods for making disinfecting compositions based on phototherapy, systems for use in disinfecting with a combination of photosensitizers, and the disinfecting compositions themselves, are described. Concentrations of the photosensitizers can be based on the particular light source and the wavebands or fluence rates emitted by the light source for maximum singlet oxygen generation. Concentrations of the photosensitizers can also be based on the quantum yield of the photosensitizers.
-
公开(公告)号：US20220054549A1
公开(公告)日：2022-02-24
申请号：US17435535
申请日：2020-03-17
发明人： Thor Wagner , Jaya Sahni
摘要： Some aspects of the methods and compositions provided herein relate to the disruption of at least one CD4 gene in a cell, such as a CD4+ T cell. In some embodiments, the disruption comprises use of a CRISPR guide polynucleotide. Some embodiments also include the preparation and use of a cell having at least one disrupted CD4 gene and a chimeric antigen receptor (CAR). Some aspects of the methods and compositions provided herein relate to CARs, such as an anti-CD4 CAR or an anti-CD19 CAR, and use to treat disorders including HIV, acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).
-
公开(公告)号：US20220054149A1
公开(公告)日：2022-02-24
申请号：US17244610
申请日：2021-04-29
申请人： University of Washington , Seattle Children's Hospital (dba Seattle Children's Research Institute)
发明人： James Chen , Tanner Clark , Thomas Lendvay
摘要： An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.
-
公开(公告)号：US20210346431A1
公开(公告)日：2021-11-11
申请号：US16971801
申请日：2019-02-22
申请人： ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION , SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
发明人： Richard MESSMANN , Christopher Paul LEAMON , Haiyan CHU , Yingjuan June LU , Philip Stewart LOW , Michael C. JENSEN , James MATTHAEI , Navin Robert Charles PINTO , Julie Ruggieri PARK
IPC分类号： A61K35/17 , C07K14/705 , A61K47/55 , A61P35/00
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号：US20210324381A1
公开(公告)日：2021-10-21
申请号：US17050601
申请日：2019-04-24
发明人： David J. Rawlings , Daniel Thomson , Iram F. Khan
IPC分类号： C12N15/11 , C12N9/22 , C12N15/90 , C07K14/705 , C12N15/87 , C12N15/86 , A61K38/46 , A61K31/7088
摘要： Described herein are compositions, systems, and methods for treating, inhibiting, or ameliorating X-linked hyper IgM syndrome (X-HIGM) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate X-HIGM. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous CD40LG locus.
-
公开(公告)号：US20210324083A1
公开(公告)日：2021-10-21
申请号：US17271813
申请日：2019-08-29
发明人： Adam Johnson , Michael C. Jensen
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , C07K14/71
摘要： Embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to B7H3. Some embodiments relate to cell-based immunotherapy targeting tumors, such as tumors comprising B7H3+ cells.
-
10.发明申请公开(公告)号：US20210269502A1
公开(公告)日：2021-09-02
申请号：US17165119
申请日：2021-02-02
发明人： Michael C. Jensen , Adam Johnson
IPC分类号： C07K14/705 , C07K14/56 , C07K14/555 , C07K14/725
摘要： The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.034 秒)
